Long-term outcome and risk factor analysis of tricuspid valve replacement for adult patients with congenitally corrected transposition of great arteries
10.7507/1007-4848.201811072
- VernacularTitle:三尖瓣置换术治疗成人先天性矫正性大动脉转位的远期临床结果及其危险因素分析
- Author:
LI Qi
1
;
DENG Long
1
;
XU Jianping
1
;
SUN Hansong
1
;
LIU Sheng
1
;
SONG Yunhu
1
Author Information
1. Department of Adult Cardiac Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, 100037, P.R.China
- Publication Type:Journal Article
- Keywords:
Tricuspid valve replacement;
congenital heart diseases;
corrected transposition of the great artery
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2019;26(9):884-888
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the long-term clinical effect and risk factors of tricuspid valve replacement (TVR) as a relief treatment for adult patients with congenitally corrected transposition of the great artery (CCTGA). Method We retrospectively analyzed the clinical data of 47 adult patients with CCTGA who underwent tricuspid valve replacement in Fuwai Hospital between 2000 and 2017 year. There were 27 males and 20 females with operation age of 14–62 (38.8±13.5) years. Preoperative echocardiography showed moderate or more tricuspid regurgitation in all patients. The basic data of patients before and during operation were recorded. Survival was followed up by telephone and ultrasound report. Results The average follow-up time was 6.5±3.7 years. The 1-year, 5-year and 10-year survival rate or the incidence of heart transplant-free was 94.6%, 90.5% and 61.7%, respectively. During the follow-up period, the long-term right ventricular ejection fraction of most patients (>90%) was still greater than or equal to 40%. Increased preoperative right ventricular end diastolic diameter (RVEDD) was a risk factor for death or heart transplantation (risk ratio 1∶11, P=0.04). The survival rate of patients with RVEDD (>60 mm) before operation was significantly reduced (P=0.032). Conclusion TVP is a feasible treatment for adult patients with CCTGA. The increase of preoperative RVEDD is a risk factor for long-term mortality.
